Navigation Links
Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Date:3/13/2008

SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Senior Vice President and CFO William R. LaRue will present a corporate overview on Thursday, March 20, 2008 at 11:00am Eastern Time (8:00am Pacific Time) during the Cowen and Company 28th Annual Health Care Conference at the Marriott Copley Place in Boston, Massachusetts.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com. To access the presentation, click on the Investor Relations tab and then click on the link entitled "Events and Presentations" on the left side of the screen. A replay of the webcast will available approximately one hour after the live webcast concludes and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue

SVP & Chief Financial Officer

Cadence Pharmaceuticals, Inc.

858-436-1400

Anna Gralinska

Director, Investor Relations

Cadence Pharmaceuticals, Inc.

(858) 436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
2. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
3. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
9. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. NPS Pharmaceuticals Reports 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... ... antibody therapeutics from millions-diverse immune repertoires, announces launch of its new Surge(TM) ... Dave Johnson, PhD, CEO of GigaGen, will present on Surge at the conference. ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting has ... years. One of the biggest challenges faced by life sciences, biotech and pharmaceuticals companies ... team is Kati Abraham , who is well known in the industry and ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... solutions, today announced that its Anzo Smart Data Lake® (Anzo SDL) solution ... category for the 2017 Software & Information Industry Association (SIIA) CODiE Awards. ...
(Date:6/15/2017)... ... June 15, 2017 , ... Cybrexa Therapeutics, ... B round of financing in the amount of $6 million. An investment vehicle ... in the round. , The Series B funding will enable Cybrexa to complete ...
Breaking Biology Technology:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):